Axsome Therapeutics Inc

Research Axsome Therapeutics Inc (AXSM) on Bullrun: market cap USD 12.41B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerAXSM
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 12.41B
• Financial periodFY2025
• RevenueUSD 638.50M
• Revenue growth65.5%
• Net income-USD 183.17M
• Free cash flow-USD 93.89M

Valuation Snapshot

latest market cap is USD 12.41B.

About Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults;

Frequently asked questions

What is Axsome Therapeutics Inc's market cap?

Axsome Therapeutics Inc's market capitalization is USD 12.41B.

What does Axsome Therapeutics Inc do?

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.